Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Abstract

Background Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol. Methods 2838 patients aged 40-75 years in 132 centres in the UK and Ireland were randomised to placebo (n=1410) or atorvastatin 10 mg daily (n=1428). Study entrants had no documented previous history of cardiovascular disease, an LDL-cholesterol concentration of 4.14 mmol/L or lower, a fasting triglyceride amount of 6.78 mmol/L or less, and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension. The primary endpoint was time to first occurrence of the following: acute coronary heart disease events, coronary revascularisation, or stroke. Analysis was by intention to treat. Findings The trial was terminated 2 years earlier than expected because the prespecified early stopping rule for efficacy had been met. Median duration of follow-up was 3.9 years (IQR 3.0-4.7). 127 patients allocated placebo (2.46 per 100 person-years at risk) and 83 allocated atorvastatin (1.54 per 100 person-years at risk) had at least one major cardiovascular event (rate reduction 37% [95% CI -52 to -17], p=0.001). Treatment would be…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)16895-5

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Oborne, 2003, Application of evidence-based criteria of appropriate aspirin and appropriate lipid-lowering therapy in diabetic inpatients, Int J Pharmacy Practice, 11, R73
  2. Leiter, 2004, The AUDIT Study: a worldwide survey of physicians attitudes about diabetic dyslipidaemia, Diabetes, 53, A285

Cited by

See all 3,755

Metadata

Authors
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H.
Affiliations
  • The Royal Free Hospital (GB)
  • University College London (GB)
  • Manchester Royal Infirmary (GB)
  • Queen Mary University of London (GB)
Corresponding author
Colhoun, Helen M
Venue
The Lancet
Publisher
Elsevier BV
Published
2004-08
Volume
364
Issue
9435
Pages
685-696
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2107295258
Cited by
3,755
References
33
Citations by year
2026: 40 · 2025: 46 · 2024: 84 · 2023: 102 · 2022: 96 · 2021: 99 · 2020: 122 · 2019: 121 · 2018: 159 · 2017: 148 · 2016: 129 · 2015: 176 · 2014: 191 · 2013: 189 · 2012: 199
FWCI
287.45
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
atorvastatin, type 2 diabetes, primary prevention, cardiovascular disease, statins, lipid-lowering therapy, major cardiovascular events, acute coronary heart disease, coronary revascularization, stroke, cardiovascular mortality, LDL cholesterol, early stopping rules, retinopathy, albuminuria, hypertension, smoking, triglycerides, adverse events, drug safety, cost-effectiveness
MeSH terms
Atorvastatin, Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(04)16895-5
The paper
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004). Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(04)16895-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.